Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials

Ravi A. Thakker, Ayman Elbadawi, Aiham Albaeni, Christopher Perez, Syed Mustajab Hasan, Jose Iturrizaga Murrieta, Ahmed Almustafa, Alexander Duarte, Rafic Berbarie, Khaled F. Chatila, Wissam Khalife

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Soluble guanylate cyclase (sGC) agents have been shown to have possible beneficial effects in heart failure treatment. Unfortunately, the role of sGC in HFpEF has not been shown to be efficacious based on recent trials. The CAPACITY HFpEF and VITALITY-HFpEF trials independently showed that sGC does not improve 6-minute walk test (6MWT) distance or the Kansas City Cardiomyopathy Questionnaire (KCCQ) physical limitation score (PLS). The objective of this study was to analyze current data on the 6MWT and KCCQ PLS score from trials that included patients with HFpEF treated with sGC. Using MEDLINE and Cochrane databases, meta-analysis and systematic review was performed looking at data in the CAPACITY HFpEF and VITALITY-HFpEF trials. For safety analysis we evaluated serious adverse events between the CAPACITY HFpEF, VITALITY-HFpEF, SOCRATES-PRESERVED, and DILATE-1trials. A total of 2 trials were analyzed to assess 6MWT and KCCQ score. The total number of combined patients from both trials assessing 6MWT distance in sGC vs placebo therapy were 620 with 309 in the treatment group and 311 in the placebo group. The total number of combined patients from both trials assessing KCCQ score outcomes were 583 with 280 in the treatment group and 303 in the placebo group. A total of 4 trials were evaluated for safety analysis with a total of 987 patients with 529 in the treatment group and 458 in the placebo group. The analysis did not demonstrate significant difference in 6MWT (P = 0.97), KCCQ PLS (P = 0.83), or serious adverse events (P = 0.67).

Original languageEnglish (US)
Article number100924
JournalCurrent Problems in Cardiology
Volume47
Issue number9
DOIs
StatePublished - Sep 2022

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials'. Together they form a unique fingerprint.

Cite this